Bryostatin-1: A novel PKC inhibitor in clinical development

The extended protein kinase C superfamily

MELLOR, H., & Parker, P. J. (1998) · Biochemical Journal · doi:10.1042/bj3320281 · Cited by 1,539 · see citing works

Matrix metalloproteinase inhibitors

Wojtowicz‐Praga, S., Dickson, R. B., & Hawkins, M. (1997) · Investigational New Drugs · doi:10.1023/a:1005722729132 · Cited by 524 · see citing works

A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis

Ruvolo, P. P., Deng, X., Carr, B. K., & May, W. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25436 · Cited by 452 · see citing works

Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

Kraft, A. S., Smith, J. B., & Berkow, R. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1334 · Cited by 257 · see citing works

Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells.

Hocevar, B. A., & Fields, A. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52396-6 · Cited by 248 · see citing works

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230 · see citing works

Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.

May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., & Davidson, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47099-8 · Cited by 219 · see citing works

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.

Wender, P. A., CRIBBS, C. M., Koehler, K. F., Sharkey, N. A., Herald, C. L., Kamano, Y., Pettit, G. R., & Blumberg, P. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7197 · Cited by 201 · see citing works

Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia

Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01642.x · Cited by 187 · see citing works

Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases

Bruns, C. J., Liu, W., Davis, D. W., Shaheen, R. M., McConkey, D. J., Wilson, M. R., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3 · Cited by 187 · see citing works

Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor Induction In Vivo

Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H. R. H., Talbot, D., Ganesan, T. S., Pettit, G. R., Balkwill, F. R., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.22.1812 · Cited by 187 · see citing works

Chemistry and clinical biology of the bryostatins

Mutter, R., & Wills, M. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00150-4 · Cited by 178 · see citing works

1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells.

Strum, J. C., Small, G. W., Pauig, S. B., & Daniel, L. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40706-x · Cited by 163 · see citing works

Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C.

Fields, A. P., Pettit, G. R., & May, W. S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68471-6 · Cited by 163 · see citing works

Ubiquitination of Protein Kinase C-α and Degradation by the Proteasome

Lee, H., Smith, L., Pettit, G. R., Vinitsky, A., & Smith, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.35.20973 · Cited by 163 · see citing works

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A. T., Testa, N. G., Stern, P. L., McDermott, R. H., Potter, M., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.352 · Cited by 145 · see citing works

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

Hornung, R. L., Pearson, J. W., Beckwith, M., & Longo, D. L. (1992) · PubMed · Cited by 134 · see citing works

Protein Kinase C (PKC) Inhibits Fas Receptor-induced Apoptosis through Modulation of the Loss of K+ and Cell Shrinkage

Gómez-Angelats, M., Bortner, C. D., & Cidlowski, J. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909563199 · Cited by 125 · see citing works

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion

Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P. L., Young, R., Brenchley, P. E., Chang, J., Owens, S. E., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.356 · Cited by 125 · see citing works

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian, M. L., Mohammad, R. M., Eilender, D., Hulburd, K., Rodriguez, D. H., Pemberton, P. A., Pluda, J. M., Dan, M., Pettit, G. R., Chen, B. D. M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.56 · Cited by 114 · see citing works

Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.

Kennedy, M. J., Prestigiacomo, L. J., Tyler, G., May, W. S., & Davidson, N. E. (1992) · PubMed · Cited by 105 · see citing works

Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro

Jones, R., Sharkis, S. J., Miller, C., Rowinsky, E. K., Burke, P., & May, W. S. (1990) · Blood · doi:10.1182/blood.v75.6.1319.bloodjournal7561319 · Cited by 98 · see citing works

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian, M. L., Mohammad, R. M., Shurafa, M. S., Hulburd, K., Pemberton, P., Rodriguez, D. H., Spadoni, V., Eilender, D. S., Murgo, A. J., Wall, N. R., et al. (2000) · PubMed · Cited by 97 · see citing works

Successful treatment of murine melanoma with bryostatin 1.

Schuchter, L. M., Esa, A. H., May, W. S., Laulis, M. K., Pettit, G. R., & Hess, A. D. (1991) · PubMed · Cited by 94 · see citing works

Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C

Isakov, N., Galron, D., Mustelin, T., Pettit, G. R., & Altman, A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.4.1195 · Cited by 92 · see citing works

Protein Kinase C Targeting in Antineoplastic Treatment Strategies

Jarvis, W. D., & Grant, S. (1999) · Investigational New Drugs · doi:10.1023/a:1006328303451 · Cited by 86 · see citing works

Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-d-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells

Jarvis, W. D., Povirk, L. F., Turner, A., Traylor, R. S., Gewirtz, D. A., Pettit, G. R., & Grant, S. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90484-7 · Cited by 85 · see citing works

A phase II study of bryostatin 1 in metastatic malignant melanoma

Propper, D., Macaulay, V. M., O'Byrne, K. J., Braybrooke, J. P., Wilner, S., Ganesan, T., Talbot, D., & Harris, A. L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.680 · Cited by 83 · see citing works

A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.

Zonder, J. A., Shields, A. F., Zalupski, M. M., Chaplen, R., Heilbrun, L. K., Arlauskas, P., & Philip, P. A. (2001) · PubMed · Cited by 82 · see citing works

Regulation of Caspase Activation and cis-Diamminedichloroplatinum(II)-Induced Cell Death by Protein Kinase C

Basu, A., & Akkaraju, G. R. (1999) · Biochemistry · doi:10.1021/bi982854q · Cited by 80 · see citing works

Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.

Trenn, G., Pettit, G. R., Takayama, H., Hu‐Li, J., & Sitkovsky, M. V. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.2.433 · Cited by 78 · see citing works

Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2.

Asiedu, C. K., Biggs, J. R., Lilly, M. B., & Kraft, A. S. (1995) · PubMed · Cited by 74 · see citing works

Activation of human T lymphocytes by bryostatin.

Hess, A. D., Silanskis, M., Esa, A. H., Pettit, G. R., & May, W. S. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.10.3263 · Cited by 70 · see citing works

Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain

Vries, D. J. D., Herald, C. L., Pettit, G. R., & Blumberg, P. M. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90097-4 · Cited by 69 · see citing works

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

Blackhall, F. H., Ranson, M., Radford, J. A., Hancock, B. W., Soukop, M., McGown, A. T., Robbins, A. K., & Halbert, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1624 · Cited by 68 · see citing works

The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.

Mohammad, R. M., Wall, N. R., Dutcher, J. A., & Al-Katib, A. M. (2000) · PubMed · Cited by 66 · see citing works

Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60).

Kraft, A. S., Vv, B., & Ws, M. (1987) · PubMed · Cited by 66 · see citing works

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

Al-Katib, A. M., Smith, M. R., Kamanda, W. S., Pettit, G. R., Hamdan, M., Mohamed, A. N., Chelladurai, B. S., & Mohammad, R. M. (1998) · PubMed · Cited by 65 · see citing works

gamma-Interferon plays a key role in T-cell-induced tumor regression.

Tuttle, T. M., McCrady, C. W., Inge, T. H., Salour, M., & Bear, H. D. (1993) · PubMed · Cited by 64 · see citing works

Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)

Wang, S., Guo, C., Castillo, A., Dent, P., & Grant, S. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00188-9 · Cited by 63 · see citing works

Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells

Drexler, H. G., Gignac, S. M., Jones, R., Cs, S., Pettit, G., & Hoffbrand, A. V. (1989) · Blood · doi:10.1182/blood.v74.5.1747.bloodjournal7451747 · Cited by 63 · see citing works

Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937)

Vrana, J. A., Saunders, A. M., Chellappan, S., & Grant, S. (1998) · Differentiation · doi:10.1046/j.1432-0436.1998.6310033.x · Cited by 62 · see citing works

The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF‐7 breast carcinoma cells

Tanwell, C. S., Gescher, A. J., Bradshaw, T. D., & Pettit, G. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560420 · Cited by 62 · see citing works

Regulation of Motility and Protease Expression in PKC-Mediated Induction of MCF-7 Breast Cancer Cell Invasiveness

Johnson, M. D., Torri, J. A., Lippman, M. E., & Dickson, R. B. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4336 · Cited by 62 · see citing works

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.

Koutcher, J. A., Motwani, M., Zakian, K. L., Li, X. K., Matei, C., Dyke, J. P., Ballon, D., Yoo, H. H., & Schwartz, G. K. (2000) · PubMed · Cited by 60 · see citing works

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

Dale, I. L., & Gescher, A. J. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430129 · Cited by 59 · see citing works

Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.

Tuttle, T. M., Inge, T. H., Bethke, K. P., McCrady, C. W., Pettit, G. R., & Bear, H. D. (1992) · PubMed · Cited by 56 · see citing works

Evidence for Protein Kinase C-Dependent and -Independent Activation of Mitogen-Activated Protein Kinase in T Cells: Potential Role of Additional Diacylglycerol Binding Proteins

Puente, L. G., Stone, J. C., & Ostergaard, H. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6865 · Cited by 54 · see citing works

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma

Mohammad, R. M., Diwakaran, H., Maki, A., Emara, A. M., Pettit, G. R., Redman, B. G., & Al-Katib, A. M. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00037-o · Cited by 53 · see citing works

The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

Szállási, Z., Du, L., Levine, R., Lewin, N. E., Nguyen, P. N., Williams, M. D., Pettit, G. R., & Blumberg, P. M. (1996) · PubMed · Cited by 51 · see citing works

Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

Grant, S., Roberts, J. D., Poplin, E. A., Tombes, M. B., Kyle, B., Welch, D. G., Carr, M. A., & Bear, H. D. (1998) · PubMed · Cited by 51 · see citing works

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

Wang, S., Wang, Z., Boise, L., Dent, P., & Grant, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401532 · Cited by 51 · see citing works

Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.

Mohammad, R. M., Al-Katib, A. M., Pettit, G. R., & Sensenbrenner, L. (1994) · PubMed · Cited by 48 · see citing works

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

Berkow, R. L., Schlabach, L., Dodson, R., Benjamin, W. H., Pettit, G. R., Rustagi, P. K., & Kraft, A. S. (1993) · PubMed · Cited by 45 · see citing works

Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study

González, R., Ebbinghaus, S., Henthorn, T. K., Miller, D. M., & Kraft, A. S. (1999) · Melanoma Research · doi:10.1097/00008390-199912000-00010 · Cited by 45 · see citing works

Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase calpha.

Gschwend, J. E., Fair, W. R., & Powell, C. T. (2000) · PubMed · Cited by 43 · see citing works

Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.

Al-Katib, A. M., Mohammad, R. M., Dan, M., Hussein, M. E., Akhtar, A. J., Pettit, G. R., & Sensenbrenner, L. (1993) · PubMed · Cited by 43 · see citing works

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

Mohammad, R. M., Varterasian, M. L., Almatchy, V. P., Hannoudi, G. N., Pettit, G. R., & Al-Katib, A. M. (1998) · PubMed · Cited by 41 · see citing works

Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.

Hu, Z., Ma, W., Uphoff, C. C., Lanotte, M., & Drexler, H. G. (1993) · PubMed · Cited by 41 · see citing works

Establishment of a Human Pancreatic Tumor Xenograft Model

Mohammad, R. M., Dugan, M. C., Mohamed, A. N., Almatchy, V. P., Flake, T. M., Dergham, S. T., Shields, A. F., Al-Katib, A., Vaitkevicius, V. K., & Sarkar, F. H. (1998) · Pancreas · doi:10.1097/00006676-199801000-00004 · Cited by 40 · see citing works

Phase II evaluation of bryostatin-1 in metastatic melanoma

Bedikian, A. Y., Plager, C., Stewart, J. R., O'Brian, C. A., Herdman, S., Ross, M., Papadopoulos, N., Eton, O. E., Ellerhorst, J. A., & Smith, T. (2001) · Melanoma Research · doi:10.1097/00008390-200104000-00014 · Cited by 40 · see citing works

Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line

Liu, K. Z., Schultz, C., Johnston, J., Beck, F. J., al-Katib, A., Rm, M., & Mantsch, H. H. (1999) · Leukemia · doi:10.1038/sj.leu.2401463 · Cited by 37 · see citing works

c-kit expression in human megakaryoblastic leukemia cell lines

Hu, Z., Ma, W., Uphoff, C., Quentmeier, H., & Drexler, H. G. (1994) · Blood · doi:10.1182/blood.v83.8.2133.2133 · Cited by 37 · see citing works

Mitogen-activated Protein Kinase Is Involved in the Degradation of p53 Protein in the Bryostatin-1-induced Differentiation of the Acute Promyelocytic Leukemia NB4 Cell Line

Song, X., Sheppard, H. M., Norman, A. W., & Liu, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1677 · Cited by 36 · see citing works

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

Weitman, S. D., Langevin, A., Berkow, R. L., Thomas, P. J., Hurwitz, C. A., Kraft, A. S., Dubowy, R. L., Smith, D. L., & Bernstein, M. L. (1999) · PubMed · Cited by 35 · see citing works

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study

Hickman, P. H., Kemp, G. J., Thompson, C., Salisbury, A., Wade, K., Harris, A. L., & Radda, G. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.449 · Cited by 35 · see citing works

Comparison of the antitumor activity of bryostatins 1, 5, and 8

Kraft, A. S., Woodley, S., Pettit, G. R., Gao, F., Coll, J. C., & Wagner, F. H. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00688328 · Cited by 35 · see citing works

p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.

Wang, H., Mohammad, R. M., Werdell, J., & Shekhar, M. P. V. (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm.1.6.915 · Cited by 35 · see citing works

The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rγ Chain Expression

Bosco, M. C., Rottschafer, S., Taylor, L. S., Ortaldo, J. R., Longo, D. L., & Espinoza‐Delgado, I. (1997) · Blood · doi:10.1182/blood.v89.9.3402 · Cited by 34 · see citing works

Potentiation of 2-Chlorodeoxyadenosine Activity by Bryostatin 1 in the Resistant Chronic Lymphocytic Leukemia Cell Line (WSU-CLL): Association with Increased Ratios of dCK/5'-NT and Bax/Bcl-2

Mohammad, R. M., Beck, F. W. J., Katato, K., Hamdy, N., Wall, N. R., & Al-Katib, A. (1998) · Biological Chemistry · doi:10.1515/bchm.1998.379.10.1253 · Cited by 32 · see citing works

Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer

Brockstein, B., Samuels, B. L., Humerickhouse, R. A., Arrieta, R. L., Fishkin, P. A. S., Wade, J., Sosman, J. A., & Vokes, E. E. (2001) · Investigational New Drugs · doi:10.1023/a:1010628903248 · Cited by 31 · see citing works

Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia.

Lilly, M., Brown, C., Pettit, G. R., & Kraft, A. S. (1991) · PubMed · Cited by 30 · see citing works

Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1

Vrana, J. A., Wang, Z., Rao, A. S., Tang, L., Chen, J.-H., Kramer, L., & Grant, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401454 · Cited by 29 · see citing works

Proteolytic cleavage of protein kinase Cμ upon induction of apoptosis in U937 cells

Häußermann, S., Kittstein, W., Rincke, G., Johannes, F., Marks, F., & Gschwendt, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01577-x · Cited by 28 · see citing works

Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.

Wall, N. R., Mohammad, R. M., Reddy, K. B., & Al-Katib, A. M. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.5.2.165 · Cited by 28 · see citing works

Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.

Lilly, M., Tompkins, C., Brown, C., Pettit, G. R., & Kraft, A. S. (1990) · PubMed · Cited by 26 · see citing works

Overexpression of novel protein kinase C δ in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo

Porta, C. A. M. L., Dio, A. D., Porro, D., & Comolli, R. (2000) · Melanoma Research · doi:10.1097/00008390-200010020-00001 · Cited by 26 · see citing works

Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML

Elgie, A. W., Sargent, J. M., Alton, P., Peters, G. J., Noordhuis, P., Williamson, C. J., & Taylor, C. G. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00011-3 · Cited by 25 · see citing works

Bryostatin 1-Induced Modulation of the Acute Lymphoblastic Leukemia Cell Line Reh

Al-Katib, A., Mohammad, R. M., Khan, K. M., Dan, M. E., Pettit, G. R., & Sensenbrenner, L. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199307000-00005 · Cited by 25 · see citing works

Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.

Scala, S., Dickstein, B., Regis, J. T., Szállási, Z., Blumberg, P. M., & Bates, S. E. (1995) · PubMed · Cited by 24 · see citing works

Bryostatin 1-activated T cells can traffic and mediate tumor regression

Tuttle, T. M., Bethke, K. P., Inge, T. H., McCrady, C. W., Pettit, G. R., & Bear, H. D. (1992) · Journal of Surgical Research · doi:10.1016/0022-4804(92)90126-k · Cited by 23 · see citing works

Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients

Lind, D. S., Tuttle, T. M., Bethke, K. P., Frank, J. L., McCrady, C. W., & Bear, H. D. (1993) · Surgical Oncology · doi:10.1016/s0960-7404(06)80002-2 · Cited by 23 · see citing works

Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells

Vrana, J. A., Kramer, L. B., Saunders, A. M., Zhang, X.-F., Dent, P., Povirk, L. F., & Grant, S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00077-5 · Cited by 22 · see citing works

Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors

Li, Y., Mohammad, R. M., Al-Katib, A. M., Varterasian, M. L., & Chen, B. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00078-1 · Cited by 22 · see citing works

Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes

Baldwin, N. G., Rice, C. D., Tuttle, T. M., Bear, H. D., Hirsch, J. I., & Merchant, R. E. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005719700570 · Cited by 20 · see citing works

Bryostatin 1 Activates T Cells That Have Antitumor Activity

Tuttle, T. M., Inge, T. H., Wirt, C. P., Frank, J. L., McCrady, C. W., & Bear, H. D. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199208000-00001 · Cited by 20 · see citing works

In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-β-d-arabinofuranosylcytosine in human leukemia cells

Grant, S., Boise, L., Westin, E. H., Howe, C. W. S., Pettit, G. R., Turner, A., & McCrady, C. W. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90046-8 · Cited by 19 · see citing works

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro

McGown, A. T., Jayson, G. C., Pettit, G., Haran, M. S., Ward, T. H., & Crowther, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.36 · Cited by 19 · see citing works

Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation.

McBain, J. A., Pettit, G. R., & Mueller, G. C. (1990) · PubMed · Cited by 18 · see citing works

Conversion of high grade lymphoma tumor cell line to intermediate grade with tpa and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis

Al-Katib, A. M., Mohammad, R. M., Mohamed, A. N., Pettit, G. R., & Sensenbrenner, L. (1990) · Hematological Oncology · doi:10.1002/hon.2900080203 · Cited by 17 · see citing works

Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.

Mohammad, R. M., Limvarapuss, C., Hamdy, N., Dutcher, B. S., Beck, F. W., Wall, N. R., & Al-Katib, A. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.5.945 · Cited by 15 · see citing works

Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial

Bear, H. D., Roberts, J. D., Cornell, D. L., Tombes, M. B., & Kyle, B. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620100199 · Cited by 14 · see citing works

Bryostatin/Ionomycin-Activated T Cells Mediate Regression of Established Tumors

Chin, C. S., Graham, L., Hamad, G. G., George, K. R., & Bear, H. D. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6181 · Cited by 14 · see citing works

Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases

Tuttle, T. M., Inge, T. H., Lind, D. S., & Bear, H. D. (1992) · Surgical Oncology · doi:10.1016/0960-7404(92)90091-x · Cited by 14 · see citing works

Adoptive Transfer of Bryostatin-Activated Tumor-Sensitized Lymphocytes Prevents or Destroys Tumor Metastases Without Expansion In Vitro

Fleming, M. D., Bear, H. D., Lipshy, K. A., Kostuchenko, P. J., Portocarero, D., McFadden, A. W., & Barrett, S. K. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199510000-00002 · Cited by 13 · see citing works

Compatibility and stability of bryostatin 1 in infusion devices

Cheung, A. P., Hallock, Y. F., Vishnuvajjala, B. R., Nguyenle, T., & Wang, E. (1998) · Investigational New Drugs · doi:10.1023/a:1006187710029 · Cited by 12 · see citing works

Induced Expression of Alpha-Enolase in Differentiated Diffuse Large Cell Lymphoma

Mohammad, R. M., Hamdan, M. Y., Maki, A., & Al-Katib, A. (2017) · Enzyme and Protein · doi:10.1159/000474967 · Cited by 11 · see citing works

Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes

Rice, C. D., Baldwin, N. G., Biron, R. T., Bear, H. D., & Merchant, R. E. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005771717409 · Cited by 11 · see citing works

Biological activity of 26-succinylbryostatin 1

Bignami, G. S., Wagner, F. H., Grothaus, P. G., Rustagi, P. K., Davis, D. E., & Kraft, A. S. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(96)00018-3 · Cited by 11 · see citing works

Effects of bryostatin 1 and rGM‐CSF on the metabolism of 1‐β‐ d ‐arabinofuranosylcytosine in human leukaemic myeloblasts

Grant, S., Jarvis, W. D., Turner, A., Wallace, H., & Pettit, G. R. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb06462.x · Cited by 11 · see citing works

Bryostatin 1 Induces Ubiquitin COOH-Terminal Hydrolase in Acute Lymphoblastic Leukemia Cells

Mohammad, R. M., Maki, A., Pettit, G. R., & Al-Katib, A. M. (2017) · Enzyme and Protein · doi:10.1159/000468636 · Cited by 11 · see citing works

Modulation of cIAP-1 by Novel Antitubulin Agents When Combined with Bryostatin 1 Results in Increased Apoptosis in the Human Early Pre-B Acute Lymphoblastic Leukemia Cell Line Reh

Wall, N. R., Mohammad, R. M., Nabha, S. M., Pettit, G. R., & Al-Katib, A. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1768 · Cited by 10 · see citing works

Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism

Cartee, C. D. L. (2000) · International Journal of Radiation Biology · doi:10.1080/09553000050151592 · Cited by 10 · see citing works

The inhibitory effects of bryostatin 1 administration on the growth of rabbit papillomas

Bodily, J. M., Hoopes, D. J., Roeder, B. L., Gilbert, S. G., Pettit, G. R., Herald, C. L., Rollins, D. N., & Robison, R. A. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00310-3 · Cited by 9 · see citing works

Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells

Hem, K. G. V. D., Dräger, A. M., Odding, J. H., LANGENHUIJSEN, M. M. A. C., & Huijgens, P. C. (1995) · Leukemia Research · doi:10.1016/0145-2126(94)00118-t · Cited by 8 · see citing works

Protective role of IL-2 during activation of T cells with bryostatin 1

Kos, F. J., Cornell, D. L., Lipke, A. B., Graham, L., & Bear, H. D. (2000) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(00)00027-8 · Cited by 8 · see citing works

Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.

Beck, F. W., Al-Katib, A. M., Ahmad, I., Wall, N. R., Liu, K. Z., Mantsch, H. H., & Mohammad, R. M. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.5.4.341 · Cited by 7 · see citing works

Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency

Hem, K. G. V. D., Dräger, A. M., Odding, J. H., & Huijgens, P. C. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00052-p · Cited by 5 · see citing works

Natural compounds for cancer treatment and prevention

Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis

Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467 · see citing works

Tetrahydrofuran-Containing Macrolides: A Fascinating Gift from the Deep Sea

Lorente, A., Lamariano‐Merketegi, J., Alberício, F., & Álvarez, M. (2013) · Chemical Reviews · doi:10.1021/cr3004778 · Cited by 354 · see citing works

Recent advances in deep-sea natural products

Skropeta, D., & Wei, L. (2014) · Natural Product Reports · doi:10.1039/c3np70118b · Cited by 233 · see citing works

An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs

Ruiz-Torres, V., Encinar, J. A., Herranz‐López, M., Pérez-Sánchez, A., Galiano, V., Barrajón‐Catalán, E., & Micol, V. (2017) · Molecules · doi:10.3390/molecules22071037 · Cited by 229 · see citing works

Protein kinase C pharmacology: refining the toolbox

Wu-Zhang, A. X., & Newton, A. C. (2013) · Biochemical Journal · doi:10.1042/bj20130220 · Cited by 195 · see citing works

Deep-sea natural products

Skropeta, D. (2008) · Natural Product Reports · doi:10.1039/b808743a · Cited by 194 · see citing works

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

DeChristopher, B. A., Loy, B. A., Marsden, M. D., Schrier, A. J., Zack, J. A., & Wender, P. A. (2012) · Nature Chemistry · doi:10.1038/nchem.1395 · Cited by 162 · see citing works

Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis

Crane, E. A., & Gademann, K. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201505863 · Cited by 159 · see citing works

Marine Antitumor Drugs: Status, Shortfalls and Strategies

Bhatnagar, I., & Kim, S. (2010) · Marine Drugs · doi:10.3390/md8102702 · Cited by 153 · see citing works

Unexpected applications of secondary metabolites

Vaishnav, P., & Demain, A. L. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.11.006 · Cited by 154 · see citing works

Total Synthesis of Bryostatin 7 via C–C Bond-Forming Hydrogenation

Lu, Y., Woo, S. K., & Krische, M. J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja205673e · Cited by 148 · see citing works

Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy

Wender, P. A., DeChristopher, B. A., & Schrier, A. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8015632 · Cited by 132 · see citing works

Neuronal ELAV proteins enhance mRNA stability by a PKCα-dependent pathway

Pascale, A., Amadio, M., Scapagnini, G., Lanni, C., Racchi, M., Provenzani, A., Govoni, S., Alkon, D. L., & Quattrone, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504702102 · Cited by 129 · see citing works

Exploring the potential of marine natural products in drug development: A comprehensive review

Banday, A. H., Azha, N. U., Farooq, R., Sheikh, S. A., Ganie, M. A., Parray, M. N., Mushtaq, H., Hameed, I., & Lone, M. A. (2024) · Phytochemistry Letters · doi:10.1016/j.phytol.2024.01.001 · Cited by 124 · see citing works

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

Kawano, T., Inokuchi, J., Eto, M., Murata, M., & Kang, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111748 · Cited by 120 · see citing works

Comprehensive Structure–Activity Relationship Studies of Macrocyclic Natural Products Enabled by Their Total Syntheses

Itoh, H., & Inoue, M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00063 · Cited by 119 · see citing works

Total Synthesis of Bryostatin 9

Wender, P. A., & Schrier, A. J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203034k · Cited by 118 · see citing works

New Approaches to the Total Synthesis of the Bryostatin Antitumor Macrolides

Hale, K. J., & Manaviazar, S. (2010) · Chemistry - An Asian Journal · doi:10.1002/asia.200900634 · Cited by 115 · see citing works

CRISPR-mediated Activation of Latent HIV-1 Expression

Limsirichai, P., Gaj, T., & Schaffer, D. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.213 · Cited by 109 · see citing works

Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV

Wender, P. A., Hardman, C., Ho, S., Jeffreys, M. S., Maclaren, J. K., Quiroz, R. V., Ryckbosch, S. M., Shimizu, A., Sloane, J. L., & Stevens, M. C. (2017) · Science · doi:10.1126/science.aan7969 · Cited by 108 · see citing works

Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy

von Schwarzenberg, K., & Vollmar, A. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.07.004 · Cited by 101 · see citing works

Trading molecules and tracking targets in symbiotic interactions

Schmidt, E. W. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.101 · Cited by 101 · see citing works

Protein kinase C intervention—the state of play

Roffey, J., Rossé, C., Linch, M. D., Hibbert, A. P., McDonald, N. Q., & Parker, P. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.019 · Cited by 100 · see citing works

Enzyme Inhibitors from Marine Invertebrates

Nakao, Y., & Fusetani, N. (2007) · Journal of Natural Products · doi:10.1021/np060600x · Cited by 90 · see citing works

Wealth of Opportunity - The C1 Domain as a Target for Drug Development

Blumberg, P. M., Kedei, N., Lewin, N. E., Yang, D., Czifra, G., Pu, Y., Peach, M. L., & Márquez, V. E. (2008) · Current Drug Targets · doi:10.2174/138945008785132376 · Cited by 82 · see citing works

Anticancer Agents from Diverse Natural Sources

Khazir, J., Riley, D. L., Pilcher, L. A., De-Maayer, P., & Mir, B. A. (2014) · Natural Product Communications · doi:10.1177/1934578x1400901130 · Cited by 82 · see citing works

Upregulation of Osteopontin by Osteocytes Deprived of Mechanical Loading or Oxygen

Gross, T. S., King, K. A., Rabaia, N. A., Pathare, P. P., & Srinivasan, S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041004 · Cited by 82 · see citing works

Apoptosis inducing lead compounds isolated from marine organisms of potential relevance in cancer treatment

Beesoo, R., Neergheen, V. S., Bhagooli, R., & Bahorun, T. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.03.005 · Cited by 78 · see citing works

Prins Cyclization of Bis(silyl) Homoallylic Alcohols to Form 2,6‐cis‐Tetrahydropyrans Containing a Geometrically Defined Exocyclic Vinylsilane: Efficient Synthesis of Ring B of the Bryostatins

Lu, J., Song, Z., Zhang, Y., Gan, Z., & Li, H. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201323 · Cited by 74 · see citing works

The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting

Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 71 · see citing works

Kinase Inhibitors from Marine Sponges

Skropeta, D., Pastro, N. J., & Zivanovic, A. (2011) · Marine Drugs · doi:10.3390/md9102131 · Cited by 71 · see citing works

Protein kinase D1: a protein of emerging translational interest

Jaggi, M. (2007) · Frontiers in bioscience · doi:10.2741/2349 · Cited by 66 · see citing works

The Phylum Bryozoa as a Promising Source of Anticancer Drugs

Figuerola, B., & Àvila, C. (2019) · Marine Drugs · doi:10.3390/md17080477 · Cited by 65 · see citing works

Conformation–activity relationships of polyketide natural products

Larsen, E. M., Wilson, M. R., & Taylor, R. E. (2015) · Natural Product Reports · doi:10.1039/c5np00014a · Cited by 58 · see citing works

Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review

Raghuvanshi, R., & Bharate, S. B. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200325110444 · Cited by 56 · see citing works

The Design, Synthesis, and Evaluation of C7 Diversified Bryostatin Analogs Reveals a Hot Spot for PKC Affinity

Wender, P. A., & Verma, V. A. (2008) · Organic Letters · doi:10.1021/ol801235h · Cited by 54 · see citing works

Total Synthesis of Bryostatin 8 Using an Organosilane‐Based Strategy

Zhang, Y., Guo, Q., Sun, X., Lu, J., Cao, Y., Pu, Q., Chu, Z., Gao, L., & Song, Z. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201711452 · Cited by 53 · see citing works

Concise Synthesis of the Bryostatin A-Ring via Consecutive C−C Bond Forming Transfer Hydrogenations

Lu, Y., & Krische, M. J. (2009) · Organic Letters · doi:10.1021/ol901096d · Cited by 53 · see citing works

PKC activator therapeutic for mild traumatic brain injury in mice.

Zohar, O., Lavy, R., Zi, X.-M., Nelson, T., Hongpaisan, J., Pick, C. G., & Alkon, D. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.001 · Cited by 45 · see citing works

Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy

Hardman, C., Ho, S., Shimizu, A., Luu-Nguyen, Q. H., Sloane, J. L., Soliman, M. S. A., Marsden, M. D., Zack, J. A., & Wender, P. A. (2020) · Nature Communications · doi:10.1038/s41467-020-15742-7 · Cited by 49 · see citing works

Natural product mode of action (MOA) studies: a link between natural and synthetic worlds

Clair, J. J. L. (2010) · Natural Product Reports · doi:10.1039/b909989c · Cited by 48 · see citing works

Translating Nature’s Library: The Bryostatins and Function‐Oriented Synthesis

Wender, P. A., Loy, B. A., & Schrier, A. J. (2011) · Israel Journal of Chemistry · doi:10.1002/ijch.201100020 · Cited by 48 · see citing works

Bioactive Compounds from Marine Heterobranchs

Àvila, C., & Angulo‐Preckler, C. (2020) · Marine Drugs · doi:10.3390/md18120657 · Cited by 47 · see citing works

Identification, Characterization and Initial Hit-to-Lead Optimization of a Series of 4-Arylamino-3-Pyridinecarbonitrile as Protein Kinase C theta (PKCθ) Inhibitors

Cole, D. C., Asselin, M., Brennan, A., Czerwiński, R., Ellingboe, J. W., Fitz, L. J., Greco, R., Huang, X., Joseph‐McCarthy, D., Kelly, M. F., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800214a · Cited by 46 · see citing works

Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds

Dayanidhi, D. L., Thomas, B. C., Osterberg, J. S., Vuong, M., Vargas, G., Kwartler, S. K., Schmaltz, E., Dunphy‐Daly, M. M., Schultz, T. F., Rittschof, D., et al. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2020.614766 · Cited by 47 · see citing works

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion

Biberacher, V., Decker, T. W., Oelsner, M., Wagner, M. M., Bogner, C., Schmidt, B., Kreitman, R. J., Peschel, C., Pastan, I. H., Büschenfelde, C. M. Z., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049155 · Cited by 45 · see citing works

Protein Kinase Cϵ (PKCϵ) Promotes Synaptogenesis through Membrane Accumulation of the Postsynaptic Density Protein PSD-95

Sen, A., Hongpaisan, J., Wang, D., Nelson, T. J., & Alkon, D. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.730440 · Cited by 46 · see citing works

Bryostatin Enhancement of Memory inHermissenda

Kuzirian, A. M., Epstein, H. T., Gagliardi, C., Nelson, T. J., Sakakibara, M., Taylor, C., Scioletti, A. B., & Alkon, D. L. (2006) · Biological Bulletin · doi:10.2307/4134558 · Cited by 43 · see citing works

Total Synthesis and Initial Biological Evaluation of New B-Ring-Modified Bryostatin Analogs

Wender, P. A., Horan, J. C., & Verma, V. A. (2006) · Organic Letters · doi:10.1021/ol0620904 · Cited by 42 · see citing works

Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma

Lam, A. P., Sparano, J. A., Vinciguerra, V. P., Ocean, A. J., Christos, P. J., Höchster, H. S., Camacho, F., Goel, S., Mani, S., & Kaubisch, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181a31920 · Cited by 41 · see citing works

The Medicinal Potential of Promising Marine Macrolides with Anticancer Activity

Qi, Y., & Ma, S. (2011) · ChemMedChem · doi:10.1002/cmdc.201000534 · Cited by 40 · see citing works

Marine Macrolides, a Promising Source of Antitumor Compounds

Napolitano, J. G., Daranas, A. H., Norte, M., & Fernández, J. J. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787313800 · Cited by 40 · see citing works

Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1

Mohanty, S., Huang, J., & Basu, A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0450 · Cited by 40 · see citing works

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

Roberts, J. D., Smith, M. R., Feldman, E. J., Cragg, L., Millenson, M. M., Roboz, G. J., Honeycutt, C., Thune, R., Padavic‐Shaller, K., Carter, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2730 · Cited by 39 · see citing works

Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C–C Bond Formation: Potency Does Not Confer Bryostatin-like Biology

Ketcham, J. M., Volchkov, I., Chen, T., Blumberg, P. M., Kedei, N., Lewin, N. E., & Krische, M. J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08695 · Cited by 37 · see citing works

Bryostatin-1: a promising compound for neurological disorders

Tian, Z., Lu, X.-T., Jiang, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1187411 · Cited by 36 · see citing works

Bryostatin-1, a Naturally Occurring Antineoplastic Agent, Acts as a Toll-like Receptor 4 (TLR-4) Ligand and Induces Unique Cytokines and Chemokines in Dendritic Cells

Ariza, M. E., Ramakrishnan, R., Singh, N. P., Chauhan, A., Nagarkatti, P. S., & Nagarkatti, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135921 · Cited by 36 · see citing works

Bryostatin 1 modulates β-catenin subcellular localization and transcription activity through protein kinase D1 activation

Jaggi, M., Chauhan, S. C., Du, C., & Balaji, K. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0119 · Cited by 36 · see citing works

Synthesis of seco -B-Ring Bryostatin Analogue WN-1 via C–C Bond-Forming Hydrogenation: Critical Contribution of the B-Ring in Determining Bryostatin-like and Phorbol 12-Myristate 13-Acetate-like Properties

Andrews, I. P., Ketcham, J. M., Blumberg, P. M., Kedei, N., Lewin, N. E., Peach, M. L., & Krische, M. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja507825s · Cited by 35 · see citing works

“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced LymphomaIn Vivo

DeChristopher, B. A., Fan, A. C., Felsher, D. W., & Wender, P. A. (2012) · Oncotarget · doi:10.18632/oncotarget.438 · Cited by 35 · see citing works

Inhibitors of signal transduction protein kinases as targets for cancer therapy

Mikalsen, T., Gerits, N., & Moens, U. L. (2006) · Biotechnology annual review · doi:10.1016/s1387-2656(06)12006-2 · Cited by 34 · see citing works

Measuring tumor response and shape change on CT: esophageal cancer as a paradigm

Schwartz, L. H., Colville, J., Ginsberg, M. S., Wang, L., Mazumdar, M., Kalaigian, J., Hricak, H., Ilson, D. H., & Schwartz, G. K. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl058 · Cited by 34 · see citing works

Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs

Wender, P. A., Nakagawa, Y., Near, K. E., & Staveness, D. (2014) · Organic Letters · doi:10.1021/ol502491f · Cited by 32 · see citing works

Natural Marine Products: Anti-Colorectal Cancer In Vitro and In Vivo

Han, N., Li, J., & Li, X. (2022) · Marine Drugs · doi:10.3390/md20060349 · Cited by 32 · see citing works

Synthesis and PKC Binding of a New Class of A-Ring Diversifiable Bryostatin Analogues Utilizing a Double Asymmetric Hydrogenation and Cross-Coupling Strategy

Wender, P. A., & Horan, J. C. (2006) · Organic Letters · doi:10.1021/ol0618149 · Cited by 32 · see citing works

Protein Kinase C

El‐Rayes, B. F., Ali, S. S., Philip, P. A., & Sarkar, F. H. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815ceaf7 · Cited by 31 · see citing works

From the Sea to Anticancer Therapy

Russo, P., Nastrucci, C., & Cesario, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796642652 · Cited by 30 · see citing works

Characterization and engineering of the biosynthesis gene cluster for antitumor macrolides PM100117 and PM100118 from a marine actinobacteria: generation of a novel improved derivative

García‐Salcedo, R., Olano, C., Gómez, C., Fernández, R., Braña, A. F., Méndez, C., de la Calle, F., & Salas, J. A. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0443-5 · Cited by 29 · see citing works

Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies

Shetu, S. A., & Bandyopadhyay, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073706 · Cited by 28 · see citing works

Biology, pathology, and therapeutic targeting of RAS

Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 28 · see citing works

C1 Domain-Targeted Isophthalate Derivatives Induce Cell Elongation and Cell Cycle Arrest in HeLa Cells

Talman, V., Tuominen, R. K., af Gennäs, G. B., Yli‐Kauhaluoma, J. T., & Ekokoski, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020053 · Cited by 28 · see citing works

A High-Throughput Cell-Based Assay to Identify Specific Inhibitors of Transcription Factor AP-1

Ruocco, K. M., Goncharova, E. I., Young, M. R., Colburn, N. H., McMahon, J. B., & Henrich, C. J. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106296686 · Cited by 27 · see citing works

Toward a Biorelevant Structure of Protein Kinase C Bound Modulators: Design, Synthesis, and Evaluation of Labeled Bryostatin Analogues for Analysis with Rotational Echo Double Resonance NMR Spectroscopy

Loy, B. A., Lesser, A. B., Staveness, D., Billingsley, K. L., Cegelski, L., & Wender, P. A. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b00886 · Cited by 26 · see citing works

Targeting PKC in microglia to promote remyelination and repair in the CNS

Kim, P. M., & Kornberg, M. D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.008 · Cited by 24 · see citing works

Some Phorbol Esters Might Partially Resemble Bryostatin 1 in their Actions on LNCaP Prostate Cancer Cells and U937 Leukemia Cells

Kedei, N., Lubart, E. S., Lewin, N. E., Telek, A., Lim, L., Mannan, P., Garfield, S. H., Kraft, M. B., Keck, G. E., Kolusheva, S., et al. (2011) · ChemBioChem · doi:10.1002/cbic.201100064 · Cited by 25 · see citing works

Inhibition of Inflammation, Suppression of Matrix Metalloproteinases, Induction of Neurogenesis, and Antioxidant Property Make Bryostatin-1 a Therapeutic Choice for Multiple Sclerosis

Safaeinejad, F., Bahrami, S., Redl, H. R., & Niknejad, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00625 · Cited by 24 · see citing works

Phase I Study of Bryostatin 1 and Gemcitabine

El-Rayes, B. F., Gadgeel, S. M., Shields, A. F., Manza, S. G., LoRusso, P. M., & Philip, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1419 · Cited by 24 · see citing works

Achyranthes aspera L. leaf extract induced anticancer effects on Dalton's Lymphoma via regulation of PKCα signaling pathway and mitochondrial apoptosis

Singh, R. K., Verma, P. K., Kumar, A., Kumar, S., & Acharya, A. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114060 · Cited by 23 · see citing works

Role of the A-Ring of Bryostatin Analogues in PKC Binding: Synthesis and Initial Biological Evaluation of New A-Ring-Modified Bryologs

Wender, P. A., Clarke, M. O., & Horan, J. C. (2005) · Organic Letters · doi:10.1021/ol0504650 · Cited by 23 · see citing works

Advanced Technologies for Large Scale Supply of Marine Drugs

Martínez, H., Santos, M., Pedraza, L., & Testera, A. M. (2025) · Marine Drugs · doi:10.3390/md23020069 · Cited by 22 · see citing works

Improved Protein Kinase C Affinity through Final Step Diversification of a Simplified Salicylate-Derived Bryostatin Analog Scaffold

Wender, P. A., & Staveness, D. (2014) · Organic Letters · doi:10.1021/ol502492b · Cited by 22 · see citing works

Phosphorylation controls a dual-function polybasic nuclear localization sequence in the adapter protein SH2B1β to regulate its cellular function and distribution

Maures, T. J., Su, H.-W., Argetsinger, L. S., Grinstein, S., & Carter‐Su, C. (2011) · Journal of Cell Science · doi:10.1242/jcs.078949 · Cited by 22 · see citing works

Genetic variants of the peroxisome proliferator‐activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer

Liu, X., Qian, D., Liu, H., Abbruzzese, J. L., Luo, S., Walsh, K. M., & Wei, Q. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23208 · Cited by 21 · see citing works

PKCη as a therapeutic target in glioblastoma multiforme

Martin, P. M., & Hussaini, I. M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.299 · Cited by 21 · see citing works

Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells

Hammond, C., Shi, Y., Mena, J., Tomic, J., Cervi, D. N., He, L., Millar, A. E., Debenedette, M. A., Schuh, A. C., Baryza, J. L., et al. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00004 · Cited by 21 · see citing works

Synthetisch gewonnene Naturstofffragmente in der Wirkstoffentwicklung

Crane, E. A., & Gademann, K. (2016) · Angewandte Chemie · doi:10.1002/ange.201505863 · Cited by 20 · see citing works

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death

Staveness, D., Abdelnabi, R., Schrier, A. J., Loy, B. A., Verma, V. A., DeChristopher, B. A., Near, K. E., Neyts, J. H., Delang, L., Leyssen, P., et al. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01016 · Cited by 20 · see citing works

Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action

Kedei, N., Telek, A., Michalowski, A. M., Kraft, M. B., Li, W., Poudel, Y. B., Rudra, A., Petersen, M. E., Keck, G. E., & Blumberg, P. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.028 · Cited by 20 · see citing works

Protein kinase C inhibitors: a patent review (2008 – 2009)

Sobhia, M. E., Grewal, B. K., Paul, S., Patel, J. A., Kaur, A., Haokip, T., & Kokkula, A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.805205 · Cited by 19 · see citing works

Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives

Tisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 18 · see citing works

Overexpression of PKCε sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1

Powell, C. T., & Yin, L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21511 · Cited by 18 · see citing works

Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges

Zhang, T., Ouyang, Z., Zhang, Y., Sun, H., Kong, L., Xu, Q., Qu, J., & Sun, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.22109 · Cited by 18 · see citing works

Identification of protein kinase C isozymes involved in the anti-proliferative and pro-apoptotic activities of 10-Methyl-aplog-1, a simplified analog of debromoaplysiatoxin, in several cancer cell lines

Hanaki, Y., Shikata, Y., Kikumori, M., Hotta, N., Imoto, M., & Irie, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.052 · Cited by 17 · see citing works

Rethinking the Role of Natural Products: Function‐Oriented Synthesis, Bryostatin, and Bryologs

Wender, P. A., Donnelly, A. C., Loy, B. A., Near, K. E., & Staveness, D. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527676545.ch14 · Cited by 17 · see citing works

Marine-derived secondary metabolites in oncology: A comprehensive review

Abuzahrah, S. S., Elbehairi, S. E. I., Bakhsh, T., Atwa, A., Juaid, N., & Mekky, R. H. (2025) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2025.100300 · Cited by 18 · see citing works

Discovery of a novel protein kinase C activator from Croton tiglium for inhibition of non-small cell lung cancer

Wang, Y., Tang, C., Yao, S., Lai, H., Li, R., Xu, J., Wang, Q., Fan, X., Wu, Q., Leung, E. L., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153100 · Cited by 16 · see citing works

Prins Cyclization of Bis(silyl) Homoallylic Alcohols to Form 2,6‐cis‐Tetrahydropyrans Containing a Geometrically Defined Exocyclic Vinylsilane: Efficient Synthesis of Ring B of the Bryostatins

Lu, J., Song, Z., Zhang, Y., Gan, Z., & Li, H. (2012) · Angewandte Chemie · doi:10.1002/ange.201201323 · Cited by 16 · see citing works

Improved and large-scale synthesis of 10-methyl-aplog-1, a potential lead for an anticancer drug

Kikumori, M., Yanagita, R. C., & Irie, K. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.11.026 · Cited by 16 · see citing works

Bryostatin 1

McIlwain, C. (2008) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.63983-2

Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug

Zonder, J. A., & Philip, P. A. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.12.2189 · Cited by 28 · see citing works

Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation

Kowalczyk, T., Staszewski, M., Markowicz-Piasecka, M., Sikora, J., Amaro, C., Picot, L., & Sitarek, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167765 · Cited by 8 · see citing works

The clinical development of the bryostatins

Clamp, A. R., & Jayson, G. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200208000-00001 · Cited by 83 · see citing works

Bryostatin 1, A New Anti-tumor Agent: From Bench to Bedside

Mohammad, R. M., Raza, S. A., Maki, A., & Al-Katib, A. (1996) · Journal of the Islamic Medical Association of North America · doi:10.5915/28-1-6175